AQUABOUNTY TECHNOLOGIES INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that AQUABOUNTY TECHNOLOGIES INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $2.47M | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | $3.14M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.17M | Mar 7, 2023 |
| FY2020 | Dec 31, 2020 | $50.2K | Mar 9, 2021 |
| FY2020 | Sep 30, 2020 | $67.8K | Mar 9, 2021 |
| FY2020 | Jun 30, 2020 | $3.0K | Mar 9, 2021 |
| FY2020 | Mar 31, 2020 | $6.8K | Mar 9, 2021 |
| FY2020 | Dec 31, 2019 | $46.4K | Mar 9, 2021 |
| FY2019 | Sep 30, 2019 | $0 | Mar 10, 2020 |
| FY2020 | Jun 30, 2019 | $42.5K | Mar 9, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $0 | Mar 8, 2018 |
| FY2017 | Sep 30, 2017 | $0 | Mar 8, 2018 |
| FY2017 | Jun 30, 2017 | $53.3K | Mar 8, 2018 |
| FY2017 | Mar 31, 2017 | $0 | Mar 8, 2018 |
| FY2017 | Dec 31, 2016 | $0 | Mar 8, 2018 |
| FY2017 | Sep 30, 2016 | $0 | Mar 8, 2018 |
| FY2017 | Jun 30, 2016 | $0 | Mar 8, 2018 |
| FY2017 | Mar 31, 2016 | $0 | Mar 8, 2018 |
| FY2017 | Dec 31, 2015 | $0 | Mar 8, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($18.49M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($149.19M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($27.56M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($22.16M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($22.32M) | Mar 7, 2023 |
| FY2020 | Dec 31, 2020 | ($6.12M) | Mar 9, 2021 |
| FY2020 | Sep 30, 2020 | ($3.65M) | Mar 9, 2021 |
| FY2020 | Jun 30, 2020 | ($3.52M) | Mar 9, 2021 |
| FY2020 | Mar 31, 2020 | ($3.11M) | Mar 9, 2021 |
| FY2020 | Dec 31, 2019 | ($3.42M) | Mar 9, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.02M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($9.63M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($13.67M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($22.32M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($22.12M) | Mar 7, 2023 |
| FY2020 | Dec 31, 2020 | ($6.04M) | Mar 9, 2021 |
| FY2020 | Sep 30, 2020 | ($3.61M) | Mar 9, 2021 |
| FY2020 | Jun 30, 2020 | ($3.50M) | Mar 9, 2021 |
| FY2020 | Mar 31, 2020 | ($3.09M) | Mar 9, 2021 |
| FY2020 | Dec 31, 2019 | ($3.40M) | Mar 9, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $203.3K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $506.2K | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $904.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $2.15M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $2.36M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $2.36M | Mar 9, 2021 |
| FY2020 | Dec 31, 2018 | $3.46M | Mar 9, 2021 |
| FY2019 | Dec 31, 2017 | $3.37M | Mar 10, 2020 |
| FY2018 | Dec 31, 2016 | $3.43M | Mar 7, 2019 |
| FY2017 | Dec 31, 2015 | $3.34M | Mar 8, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.74M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($13.86M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($24.24M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($21.01M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($20.47M) | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | ($14.29M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($11.25M) | Mar 9, 2021 |
| FY2020 | Dec 31, 2018 | ($9.82M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2017 | ($9.10M) | Mar 10, 2020 |
| FY2018 | Dec 31, 2016 | ($7.45M) | Mar 7, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $2.93M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $68.89M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $67.48M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $5.71M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $3.98M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $2.32M | Mar 9, 2021 |
| FY2020 | Dec 31, 2018 | $4.01M | Mar 9, 2021 |
| FY2019 | Dec 31, 2017 | $18.89M | Mar 10, 2020 |
| FY2018 | Dec 31, 2016 | $934.5K | Mar 7, 2019 |
| FY2017 | Dec 31, 2015 | $74.1K | Mar 8, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.34M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $34.06M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $187.55M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $213.84M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $228.44M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $125.78M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $30.23M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $27.67M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $23.73M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $5.71M | Mar 8, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.23M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $18.22M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $22.53M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $21.92M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $14.63M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $10.90M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $6.47M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $4.44M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $5.75M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $3.68M | Mar 8, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.89M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $15.84M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $165.02M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $191.92M | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | $213.80M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $114.88M | Mar 7, 2023 |
| FY2021 | Dec 31, 2019 | $23.76M | Mar 10, 2022 |
| FY2020 | Dec 31, 2018 | $23.23M | Mar 9, 2021 |
| FY2020 | Dec 31, 2017 | $17.98M | Mar 9, 2021 |
| FY2019 | Dec 31, 2016 | $2.03M | Mar 10, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($388.26M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($369.77M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($220.58M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($193.02M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($170.86M) | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | ($148.54M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($132.14M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($118.91M) | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | ($108.53M) | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | ($99.27M) | Mar 8, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $501.3K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $230.4K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $8.20M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $101.64M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $88.45M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $95.75M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $2.80M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $3.00M | Mar 10, 2020 |
| FY2019 | Dec 31, 2017 | $506.3K | Mar 10, 2020 |
| FY2019 | Dec 31, 2016 | $3.34M | Mar 10, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.12M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $3.26M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $5.06M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $8.73M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $9.22M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $8.87M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $4.60M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $3.59M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $3.08M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $2.66M | Mar 8, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (38) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (7) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (5) | Apr 1, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (38) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (7) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (5) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 7, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3.88M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 3.87M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 3.85M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 3.83M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 71.03M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | 55.50M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | 21.64M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | 15.10M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | 8.90M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | 6.46M | Mar 8, 2018 |